Trial reportBlood2016
Rapid discrimination of the phenotypic variants of von Willebrand disease.
Trial report in Blood, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05500807 (Emicizumab for Severe VON Willebrand Disease), which is not on this map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Emicizumab for Severe VON Willebrand Disease (VWD) and VWD/Hemophilia A
Who cites it
8 citing papers in PubMed, 22 citations in OpenAlex.
- Prevalence and characterization of anti-VWF antibodies in a population of patients with type 3 VWD.Blood advances · 2024Article
- von Willebrand disease.Nature reviews. Disease primers · 2024Review
- Von Willebrand Factor (VWF) multiplex activity assay differentiation of type 1 von Willebrand Disease (VWD) and variant VWD.Haemophilia : the official journal of the World Federation of Hemophilia · 2024Article
- Shear-induced acquired von Willebrand syndrome: an accomplice of bleeding events in adults on extracorporeal membrane oxygenation support.Frontiers in cardiovascular medicine · 2023Review
- Sixth Åland Island Conference on von Willebrand disease.Haemophilia : the official journal of the World Federation of Hemophilia · 2022Article
- Bleeding patterns in patients before and after diagnosis of von Willebrand disease: Analysis of a US medical claims database.Haemophilia : the official journal of the World Federation of Hemophilia · 2022Article
- One piece of the puzzle: Population pharmacokinetics of FVIII during perioperative Haemate PJournal of thrombosis and haemostasis : JTH · 2020Article
- What have we learned from large population studies of von Willebrand disease?Hematology. American Society of Hematology. Education Program · 2016Review
Corrections and comments
- Commented on by
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
Approximately 20% to 25% of patients with von Willebrand disease (VWD) have a qualitative defect of the von Willebrand factor (VWF) protein activities. Variant VWD typically is classified as type 1C, 2A, 2B, 2M, or 2N depending on the VWF activity defect. Traditionally, diagnosis has relied on multiple clinical laboratory assays to assign VWD phenotype. We developed an enzyme-linked immunosorbent assay (ELISA) to measure the various activities of VWF on a single plate and evaluated 160 patient samples enrolled in the Zimmerman Program for the Molecular and Clinical Biology of von Willebrand Disease with type 2 VWD. Using linear discriminate analysis (LDA), this assay was able to identify type 1C, 2A, 2B, 2M, or 2N VWD with an overall accuracy of 92.5% in the patient study cohort. LDA jackknife analysis, a statistical resampling technique, identified variant VWD with an overall accuracy of 88.1%, which predicts the assay's performance in the general population. In addition, this assay demonstrated correlation with traditional clinical laboratory VWF assays. The VWF multiplex activity assay may be useful as a same-day screening assay when considering the diagnosis of variant VWD in an individual patient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.